


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-91. (Cancelled)

92. (Withdrawn) A compound of formula I:



or a salt, solvate and chemically protected form thereof, wherein:

X is O or NH;


R² and R³ are independently selected from the group consisting of H, and optionally substituted C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, and phenyl-C₁₋₄ alkyl;

R¹ is an optionally substituted C₉₋₁₄ aryl group or a substituted bi-C₅₋₇ aryl group;


R^{N1} and R^{N2} are either:

- (i) independently selected from H, R, R', SO₂R, C(=O)R, (CH₂)_nNR^{N3}R^{N4}, where n is from 1 to 4 and R^{N3} and R^{N4} are independently selected from H and R, where R is optionally substituted C₁₋₄ alkyl, and R' is optionally substituted phenyl-C₁₋₄ alkyl, or
- (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C₅₋₇ heterocyclic group;

with the proviso that when R^{N1} , R^{N2} and R^2 are H, R^3 is methyl, and X is NH, then R^1 is not:



93. (Withdrawn) The compound according to claim 92, wherein R^{N1} and R^{N2} are both H.
94. (Withdrawn) The compound according to claim 92, wherein R^2 is H.
95. (Withdrawn) The compound according to claim 92, wherein R^1 is an optionally substituted biphenyl group.
96. (Previously Presented) A compound of formula II:



or a salt, solvate and chemically protected form thereof, wherein:


R^5 is selected from the group consisting of optionally substituted C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl- C_{1-4} alkyl, and phenyl- C_{1-4} alkyl;

R^4 is an optionally substituted C_{9-14} aryl group;


R^{N5} and R^{N6} are either:

- (i) independently selected from H, R, R', SO_2R , $C(=O)R$, $(CH_2)_nNR^{N7}R^{N8}$, where n is from 1 to 4 and R^{N7} and R^{N8} are independently selected from H and R, where R is optionally substituted C_{1-4} alkyl, and R' is optionally substituted phenyl- C_{1-4} alkyl, or

- (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C₅₋₇ heterocyclic group.
97. (Previously Presented) The compound according to claim 96, wherein at least one of R^{N5} and R^{N6} is H, and the other is selected from H and C(=O)Me.
98. (Canceled)
99. (Previously Presented) The compound according to claim 96, wherein R⁴ is an optionally substituted 3- or 4-C₅₋₆ aryl-C₅₋₆ aryl group.
100. (Withdrawn) A compound of formula IIIa or IIIb:



(IIIb)



(IIIa)

or a salt, solvate and chemically protected form thereof,

wherein:

R⁸ is selected from the group consisting of H, and optionally substituted C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, and phenyl-C₁₋₄ alkyl;

R⁷ is an optionally substituted bi-C₅₋₇ aryl group;



R^{N9} and R^{N10} are either:

- (i) independently selected from H, R, R', SO₂R, C(=O)R, (CH₂)_nNR^{N11}R^{N12}, where n is from 1 to 4 and R^{N11} and R^{N12} are independently selected from H and R, where R is optionally substituted C₁₋₄ alkyl, and R' is optionally substituted phenyl-C₁₋₄ alkyl, or

- (ii) together with the nitrogen atom to which they are attached, form an optionally substituted CS-7 heterocyclic group;

with the proviso that in formula IIIb, when R^{N9} , R^{N10} and R^8 are H, R^7 is not 4-phenylphenyl.

101. (Withdrawn) The compound according to claim 100, wherein R^8 is selected from H and optionally substituted C_{1-6} alkyl.
102. (Withdrawn) The compound according to claim 100, wherein R^{N9} and R^{N10} are independently selected from H and R.
103. (Withdrawn) The compound according to claim 102, wherein R^7 is an optionally substituted bi-phenyl group.
104. (Withdrawn) A compound of formula IVa or IVb:



or a salt, solvate and chemically protected form thereof, wherein:

R^{10} is selected from the group consisting of H and optionally substituted C_{1-6} alkyl;

R^9 is an optionally substituted C_{9-14} aryl group or an optionally substituted bi- C_{5-7} aryl group;

R^{N13} and R^{N14} are either:

- (i) independently selected from H, R, R' , SO_2R , $C(=O)R$, $(CH_2)_nNR^{N15}R^{N16}$, where n is from 1 to 4 and R^{N15} and R^{N16} are independently selected from

H and R, where R is optionally substituted C₁₋₄ alkyl, and R' is optionally substituted phenyl-C₁₋₄ alkyl, or

- (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C₅₋₇ heterocyclic group, with the proviso that when R¹⁰, R^{N13} and R^{N14} are H, R⁹ is not an unsubstituted naphthyl group.

105. (Withdrawn) The compound according to claim 104, wherein R¹⁰ is selected from H and optionally substituted C₁₋₆ alkyl.
106. (Withdrawn) The compound according to claim 104, wherein R^{N13} and R^{N14} are independently selected from H and R.
107. (Withdrawn) The compound according to claim 104, wherein R⁹ is an optionally substituted bi-phenyl group.
108. (Withdrawn) A method of treating a condition which can be alleviated by antagonism of a 5-HT_{2B} receptor, which method comprises administering to a patient in need of treatment an effective amount of a compound according to claim 92.
109. (Withdrawn) A method of treating a condition which can be alleviated by antagonism of a 5-HT_{2B} receptor, which method comprises administering to a patient in need of treatment an effective amount of a compound according to claim 96.
110. (Withdrawn) A method of treating a condition which can be alleviated by antagonism of a 5-HT_{2B} receptor, which method comprises administering to a patient in need of treatment an effective amount of a compound according to claim 100.
111. (Withdrawn) A method of treating a condition which can be alleviated by antagonism of a 5-HT_{2B} receptor, which method comprises administering to a

patient in need of treatment an effective amount of a compound according to claim 104.

112. (Withdrawn) The method according to claim 109, wherein the condition which can be alleviated by antagonism of a 5-HT_{2B} receptor is selected from a disorder of the GI tract, migraine, neurogenic pain, pain, anxiety, depression, benign prostatic hyperplasia, sleep disorder, panic disorder, obsessive compulsive disorder, alcoholism, hypertension, anorexia nervosa, priapism asthma, obstructive airway disease, incontinence and bladder dysfunction, disorders of the uterus and pulmonary hypertension.
113. (Withdrawn – Currently Amended) The method according to claim 112 ~~115~~, wherein the disorder of the GI tract is selected from a disorder of gastric motility, dyspepsia, GERD, and tachygastria.
114. (Withdrawn – Currently Amended) The method according to claim 112 ~~115~~ wherein the disorder of the uterus is dysmenorrhoea, pre-term labour, post-partum remodeling, endometriosis and fibrosis.
115. (New) The compound of claim 96, wherein one of R^{N5} and R^{N6} is C(=O)Me and the other is H.
116. (New)..The compound of claim 96, wherein R⁴ is a C₉₋₁₄ aryl group.
117. (New) The compound of claim 96, wherein R⁴ is a C₉₋₁₄ aryl group substituted with one or more groups selected from hydroxy, C₁₋₄ alkoxy, cyano, amino, and amido.
118. (New) The compound of claim 117, wherein R⁴ is substituted with C₁₋₄ alkoxy.
119. (New) The compound of claim 118, wherein R⁴ is substituted with methoxy.